Our trials 2019-04-12T18:31:35+12:00

Our trials …

As with all things in life you need ‘the proof of the pudding!’ to judge things. So here are some of the trials we are currently engaged on……


A 8,000 patient, multi-centre, randomised controlled trial to compare the safety and efficacy of Plasma-Lyte 148® in comparison with saline .


A multi-centre, phase II, randomised, open label, clinical trial comparing combined prophylactic intravenous paracetamol and early targeted physical cooling for fever with standard temperature management in mechanically ventilated adults without acute brain pathologies who are expected to be ventilated beyond the day after randomisation.


A randomised, embedded, multi-factorial, adaptive platform clinical trial. The Trial will simultaneously investigate the best of two or three options in 4 areas of practice for patients admitted to intensive care with pneumonia. Patients will be randomly allocated to one of the options in each of these four areas.


The TAME trial is a phase III, multi-centre, randomised, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to determine whether targeted therapeutic mild hypercapnia (TTMH) improves neurological outcome at 6 months compared to standard care (targeted normocapnia) (TN).

TARGET Protein Feasibility Study

The TARGET Protein Feasibility Study is a 120 patient, multi-centre, double-blinded, randomised, controlled, parallel-group, feasibility clinical trial.

The primary aim of the study is to determine if separation of mean daily protein delivery can be achieved using a higher protein enteral nutrition (EN) when compared to routine care EN, in mechanically ventilated patients.


The TASI Study will test the potential overall benefit of the TightRope versus syndesmotic screw fixation for ankle injuries.


The TTM2 trial is investigating whether targeted temperature management (TTM) to 33°C improves survival and neurological outcome at 6 months compared to a strategy of targeting normothermia and avoiding fever above 37.7°C.